These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 34377593)
1. Association of Ugai T; Zhao M; Shimizu T; Akimoto N; Shi S; Takashima Y; Zhong R; Lau MC; Haruki K; Arima K; Fujiyoshi K; Langworthy B; Masugi Y; da Silva A; Nosho K; Baba Y; Song M; Chan AT; Wang M; Meyerhardt JA; Giannakis M; Väyrynen JP; Nowak JA; Ogino S Oncoimmunology; 2021; 10(1):1956173. PubMed ID: 34377593 [TBL] [Abstract][Full Text] [Related]
2. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456 [TBL] [Abstract][Full Text] [Related]
3. Inverse relationship between Ugai T; Shimizu T; Kawamura H; Ugai S; Takashima Y; Usui G; Väyrynen JP; Okadome K; Haruki K; Akimoto N; Masugi Y; da Silva A; Mima K; Zhang X; Chan AT; Wang M; Garrett WS; Freeman GJ; Meyerhardt JA; Nowak JA; Song M; Giannakis M; Ogino S Clin Transl Immunology; 2023; 12(8):e1453. PubMed ID: 37538192 [TBL] [Abstract][Full Text] [Related]
4. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. Hamada T; Cao Y; Qian ZR; Masugi Y; Nowak JA; Yang J; Song M; Mima K; Kosumi K; Liu L; Shi Y; da Silva A; Gu M; Li W; Keum N; Zhang X; Wu K; Meyerhardt JA; Giovannucci EL; Giannakis M; Rodig SJ; Freeman GJ; Nevo D; Wang M; Chan AT; Fuchs CS; Nishihara R; Ogino S J Clin Oncol; 2017 Jun; 35(16):1836-1844. PubMed ID: 28406723 [TBL] [Abstract][Full Text] [Related]
5. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Masugi Y; Nishihara R; Yang J; Mima K; da Silva A; Shi Y; Inamura K; Cao Y; Song M; Nowak JA; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig S; Fuchs CS; Qian ZR; Ogino S Gut; 2017 Aug; 66(8):1463-1473. PubMed ID: 27196573 [TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368 [TBL] [Abstract][Full Text] [Related]
7. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
8. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706 [TBL] [Abstract][Full Text] [Related]
9. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721 [TBL] [Abstract][Full Text] [Related]
10. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor Hamada T; Soong TR; Masugi Y; Kosumi K; Nowak JA; da Silva A; Mu XJ; Twombly TS; Koh H; Yang J; Song M; Liu L; Gu M; Shi Y; Nosho K; Morikawa T; Inamura K; Shukla SA; Wu CJ; Garraway LA; Zhang X; Wu K; Meyerhardt JA; Chan AT; Glickman JN; Rodig SJ; Freeman GJ; Fuchs CS; Nishihara R; Giannakis M; Ogino S Oncoimmunology; 2018; 7(7):e1442999. PubMed ID: 29900052 [TBL] [Abstract][Full Text] [Related]
11. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Inaguma S; Lasota J; Wang Z; Felisiak-Golabek A; Ikeda H; Miettinen M Mod Pathol; 2017 Feb; 30(2):278-285. PubMed ID: 27813511 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840 [TBL] [Abstract][Full Text] [Related]
14. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062 [TBL] [Abstract][Full Text] [Related]
15. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881 [TBL] [Abstract][Full Text] [Related]
16. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Eklöf V; Wikberg ML; Edin S; Dahlin AM; Jonsson BA; Öberg Å; Rutegård J; Palmqvist R Br J Cancer; 2013 May; 108(10):2153-63. PubMed ID: 23660947 [TBL] [Abstract][Full Text] [Related]
17. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma. Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840 [TBL] [Abstract][Full Text] [Related]
18. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985 [TBL] [Abstract][Full Text] [Related]
19. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428 [TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]